NDAORALTABLET
Approved
Apr 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
6/8 — Strong
HYZAAR (losartan potassium and hydrochlorothiazide) by Merck & Co. is [formed from angiotensin i in a reaction catalyzed by angiotensin converting enzyme (ace, kininase ii)], is a potent vasoconstrictor, the primary vasoactive hormone of the renin-angiotensin system and an important component in the pathophysiology of hypertension. Approved for hypertension, to lower blood pressure, stroke in patients with hypertension and 3 more indications. First approved in 1995.
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYZAAR is a fixed-dose oral combination of losartan potassium (an angiotensin II receptor antagonist) and hydrochlorothiazide (a thiazide diuretic) approved to treat hypertension and reduce stroke risk in hypertensive patients. Losartan selectively blocks AT1 receptors to inhibit angiotensin II-mediated vasoconstriction and aldosterone secretion, while hydrochlorothiazide increases sodium and chloride excretion to reduce plasma volume; the combination leverages complementary mechanisms to achieve additive blood pressure reduction.
$2MPart D
LOE ApproachingDeclining
HYZAAR faces significant generic erosion with competitive pressure of 30, indicating shrinking brand team and transition focus toward post-LOE support or legacy management.
Mechanism of Action
[formed from angiotensin I in a reaction catalyzed by angiotensin converting enzyme (ACE, kininase II)], is a potent vasoconstrictor, the primary vasoactive hormone of the renin-angiotensin system and an important component in the pathophysiology of hypertension. It also stimulates aldosterone…
Pharmacologic Class:
Thiazide Diuretic
Worked on HYZAAR at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.